Painreform Ltd (PRFX) - Total Liabilities
Based on the latest financial reports, Painreform Ltd (PRFX) has total liabilities worth $2.72 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Painreform Ltd (PRFX) cash flow conversion to assess how effectively this company generates cash.
Painreform Ltd - Total Liabilities Trend (2017–2024)
This chart illustrates how Painreform Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Painreform Ltd (PRFX) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Painreform Ltd Competitors by Total Liabilities
The table below lists competitors of Painreform Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Arcadia Biosciences Inc
NASDAQ:RKDA
|
USA | $2.41 Million |
|
Nexera Energy Inc
V:NGY
|
Canada | CA$32.63 Million |
|
GRAPHANO ENERGY LTD
F:97G0
|
Germany | €25.82K |
|
RIVER TECH EO -005
F:9YQ
|
Germany | €2.04 Million |
|
Kulthorn Kirby Public Company Limited
BK:KKC
|
Thailand | ฿6.34 Billion |
|
Aclarion Inc
NASDAQ:ACON
|
USA | $699.75K |
|
Ucommune International Ltd
NASDAQ:UK
|
USA | $74.20 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Painreform Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Painreform Ltd (PRFX) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Painreform Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Painreform Ltd (2017–2024)
The table below shows the annual total liabilities of Painreform Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.70 Million | +0.37% |
| 2023-12-31 | $2.69 Million | +105.89% |
| 2022-12-31 | $1.31 Million | +31.89% |
| 2021-12-31 | $991.00K | -16.09% |
| 2020-12-31 | $1.18 Million | -82.60% |
| 2019-12-31 | $6.79 Million | +49.54% |
| 2018-12-31 | $4.54 Million | +18.08% |
| 2017-12-31 | $3.84 Million | -- |
About Painreform Ltd
PRF Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinica… Read more